<i>PALB2</i>, <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS
Melissa C. Southey(The University of Melbourne), Nichola Johnson(Institute of Cancer Research), Marjanka K. Schmidt(University of Cambridge), Elizabeth J. van Rensburg(University of Pretoria), Julian Peto(London School of Hygiene & Tropical Medicine), Rodney J. Scott(New South Wales Department of Health), Fergus J. Couch(Mayo Clinic), Peter A. Fasching(Universitätsklinikum Erlangen), Helen Tsimiklis(The University of Melbourne), Thilo Dörk(Hannover Re (Germany)), Michael J. Kerin(Ollscoil na Gaillimhe – University of Galway), Thérèse Truong(Université Paris-Sud), Kathleen Claes(Statistics Belgium), Annegien Broeks, William D. Foulkes(McGill University Health Centre), Joe Dennis(University of Cambridge), Katri Pylkäs(University of Oulu), Zhi L. Teo(The University of Melbourne), F. Ménégaux(Université Paris-Sud), Pascal Guénel(Inserm), Ian Tomlinson(University of Oxford), Matthias W. Beckmann(Universitätsklinikum Erlangen), Robert Winqvist(Oulu University Hospital), Arif B. Ekici(University Medical Center Groningen), Kyriaki Michailidou(Cyprus Institute of Neurology and Genetics), F. Marmé(Heidelberg University), Marc Tischkowitz(University of Cambridge), Christine L. Clarke(Memorial University of Newfoundland), Heli Nevanlinna(University of Helsinki), Elinor J. Sawyer(King's College London), Olivia Fletcher(Breast Cancer Care), Jorge S. Reis‐Filho(AstraZeneca (France)), Irene Catucci(IFOM), Rongxi Yang(German Cancer Research Center), Tuomas Heikkinen(University of Helsinki), Barbara Burwinkel(German Cancer Research Center), Paolo Peterlongo(IFOM), Paolo Radice(IFOM), Frans B.L. Hogervorst(The Netherlands Cancer Institute), John L. Hopper(The University of Melbourne), James G. Dowty(The University of Melbourne), Senno Verhoef(The Netherlands Cancer Institute), Jane Carpenter(The University of Sydney), Fabrice Odefrey(Institute of Biomedical Sciences, Academia Sinica), Manjeet K. Bolla(University of Cambridge), Nicola Miller(Ollscoil na Gaillimhe – University of Galway), Isabel dos‐Santos‐Silva(London School of Hygiene & Tropical Medicine), Lothar Haeberle(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 217
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k